Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
N. Mehyar, A. Mashhour, I. Islam, S. Gul, A.O. Adedeji, A.S. Askar & M. Boudjelal. (2021) Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase. SAR and QSAR in Environmental Research 32:1, pages 51-70.
Read now
Read now
Tijana Subotički, Olivera Mitrović Ajtić, Mileva Mićić, Tamara Kravić Stevović, Dragoslava Đikić, Miloš Diklić, Danijela Leković, Mirjana Gotić & Vladan P. Čokić. (2018) β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. Ultrastructural Pathology 42:6, pages 498-507.
Read now
Read now
Articles from other publishers (7)
Xiaofeng Liu, Binyou Wang, Yuan Liu, Yang Yu, Ying Wan, Jianming Wu & Yiwei Wang. (2023) JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions. Molecular Diversity.
Crossref
Crossref
Elena Inzoli, Elena Crisà, Novella Pugliese, Ivan Civettini, Giuseppe Lanzarone, Andrea Castelli, Vincenzo Martinelli, Laura Montelisciani, Laura Antolini, Carlo Gambacorti‐Passerini & Elena Maria Elli. (2022) Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia. European Journal of Haematology 110:4, pages 354-361.
Crossref
Crossref
Tasaduq H. Wani, Anindita Chakrabarty, Norio Shibata, Hiroshi Yamazaki, F. Peter Guengerich & Goutam Chowdhury. (2017) The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage. Chemical Research in Toxicology 30:8, pages 1622-1628.
Crossref
Crossref
Mary Frances McMullin, Claire N. Harrison, Dietger Niederwieser, Hilde Demuynck, Nadja Jäkel, Prashanth Gopalakrishna, Mari McQuitty, Viktoriya Stalbovskaya, Christian Recher, Koen Theunissen, Heinz Gisslinger, Jean-Jacques Kiladjian & Haifa-Kathrin Al-Ali. (2015) The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Experimental Hematology & Oncology 4:1.
Crossref
Crossref
Madappa KundrandaToufic Kachaamy. (2014) Promising new therapies in advanced pancreatic adenocarcinomas. Future Oncology 10:16, pages 2629-2641.
Crossref
Crossref
Sabari Vallath, Robert E. Hynds, Laura Succony, Sam M. Janes & Adam Giangreco. (2014) Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. European Respiratory Journal 44:2, pages 513-522.
Crossref
Crossref
Starla J. Swaim. (2014) Ruxolitinib for the treatment of primary myelofibrosis. American Journal of Health-System Pharmacy 71:6, pages 453-462.
Crossref
Crossref